Brief: Eloxx Pharmaceuticals Reports Topline Results From Phase 2 Combination Clinical Trial Of ELX-02 In Class 1 Cystic Fibrosis (CF) Patients
14/09/2022 21:12
Sept 14 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS TOPLINE RESULTS FROM PHASE 2
COMBINATION CLINICAL TRIAL OF ELX-02 IN CLASS 1 CYSTIC FIBROSIS
(CF) PATIENTS
* ELOXX PHARMACEUTICALS INC - ELX-02 WAS WELL TOLERATED WITH
NO
DRUG-RELATED SERIOUS ADVERSE EVENTS OBSERVED
* ELOXX - COMBINATION OF SUBCUTANEOUS ELX-02 WITH IVACAFTOR
DID
NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR EFFICACY ENDPOINTS IN
PHASE 2 STUDY IN CLASS 1 CF
* ELOXX PHARMACEUTICALS INC - EVIDENCE OF ACTIVITY FOR
ELX-02
OBSERVED; EFFICACY SIGNAL POTENTIALLY CONFOUNDED BY VARIABILITY
DUE TO LOW DRUG EXPOSURE
Source text for Eikon: ID:nGNX1JK6QX
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome